Comparison between SS Retail IPO and Symbiotec Pharmalab IPO.
SS Retail IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Symbiotec Pharmalab IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of SS Retail IPO is up to ₹500.00 Cr whereas the issue size of the Symbiotec Pharmalab IPO is up to ₹2,180.00 Cr. The final issue price of SS Retail IPO is and of Symbiotec Pharmalab IPO is .
| SS Retail IPO | Symbiotec Pharmalab IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹300.00 Cr | up to ₹150.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹200.00 Cr | up to ₹2,030.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹500.00 Cr | up to ₹2,180.00 Cr |
SS Retail IPO opens on , while Symbiotec Pharmalab IPO opens on . The closing date of SS Retail IPO and Symbiotec Pharmalab IPO is , and , respectively.
SS Retail IPO P/E ratio is , as compared to Symbiotec Pharmalab IPO P/E ratio of .
| SS Retail IPO | Symbiotec Pharmalab IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)SS Retail Ltd.'s revenue increased by 32% and profit after tax (PAT) rose by 50% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Symbiotec Pharmalab Ltd.'s revenue increased by 5% and profit after tax (PAT) dropped by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 75.74 | 34.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 30.94% | 12.66% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 25.78% | 11.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.60 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 32.82% | 11.79% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the SS Retail IPO Retail Individual Investors (RII) are offered 0 shares while in Symbiotec Pharmalab IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in SS Retail IPO and 0 shares in Symbiotec Pharmalab IPO.
| SS Retail IPO | Symbiotec Pharmalab IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
SS Retail IPO subscribed in total, whereas Symbiotec Pharmalab IPO subscribed .
